Bearstone Insights White Paper

Cannabis Market Analysis | Poland

Who is this report for?

Pharmaceutical companies

Potential investors

Cannabis producers

Medical professionals

Logistics sector

According to the Drug Reimbursement Bill in July 2017, the reimbursement of cannabis medicines is subject to the recommendation of the Agency for Health Technology Assessment and Tariff System (AOTMiT). In February 2018, AOTMiT recommended that the costs of medicines Bediol, Bedrocan, Bedica, Bedrolite, and Bedrobinol should not be reimbursed for a broad range of medical conditions, on the basis of a lack of scientific evidence for their efficacy.

One of the factors of interest for the market of cannabis-based medicines in Poland is the open nature of the 2017 law. It is not specified which diseases can be treated with cannabis drugs, nor is there a list of permitted products. According to various media articles, the number of Poles suffering from ailments that might be treated with medical cannabis could be anywhere from 300,000 to 1 million.